why choose us

First received: July 18, 2022

Clinical Trial: Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer

Study Status: Completed

Recruit Status: RECRUITING

Condition: Castration-resistant Prostate Cancer

Study Type: INTERVENTIONAL


Official Title: A Phase 2 Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer

Brief Summary: This is a multicenter, single-arm, two-stage open-label phase 2 study of the combination of cabozantinib + nivolumab in subjects with advanced castration-resistant prostate cancer (CRPC).

Read more